Eko Health Raises $41 Million to Scale AI-Driven Heart & Lung Disease Detection

Eko Health Raises $41 Million to Scale AI-Driven Heart & Lung Disease Detection

Client News

Related Solutions

Providing a strategic, multidisciplinary approach to help clients develop and use AI and to navigate the landscape of Big Data.
Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.

On June 5, 2024, Eko Health, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, announced it has raised $41 million in Series D financing. With participation by ARTIS Ventures, Highland Capital Partners, NTTVC and Questa Capital, the funding round will be used to expand US and global access to the company’s early disease detection platform.

The WilmerHale team advising Eko Health consisted of Joe Wyatt, Shafi Armatis and Sharon Baek.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel